Biopharma Report

Biopharma exits nearly double with $3 billion boost from EyeBio sale 

VC investment and exit activity in the biopharma sector rose in Q3. Exit value hit $9.7 billion—up from $5 billion in Q2—headlined by Merck’s $3 billion acquisition of EyeBio, an eye disease specialist backed by Bain Capital and Samsara BioCapital.

Generative AI has driven considerable excitement for applications like protein engineering, our latest Emerging Tech Research shows. Radiopharmaceuticals, which use radioactive isotopes to design targeted drugs, is another innovation hot spot.

Falling rates and liquidity pressure should keep the exit pipeline full. VC-backed biopharma companies could also benefit from loosening regulations under a Republican-led US government.